Journals / Eurasian Journal of Medicine / 2021 / Cilt: 53 - Sayı: 2

The Effects of Agomelatine Treatment on Lipopolysaccharide-Induced Septic Lung Injuries in Rats

Pages
160–161
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The histopathology results supported the molecular results.Conclusion: In this experimental study, we demonstrated for the first time the positive effects of AGO onLPS-induced sepsis in lung tissue using molecular and histopathological methods, indicating that it contributesto the prevention of lung damage

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We designed an experimental model of sepsis in rats to investigate the effects of agomelatine(AGO) on lung tissues using molecular and histopathological methods.Materials and Methods: In our experimental model, the 32 rats were divided into 4 groups: group 1: controlgroup (HEALTHY); group 2: lipopolysaccharide group (LPS); group 3: LPS plus 50 mg/kg AGO group (LPS +AGO50); and group 4: LPS plus 100 mg/kg AGO group (LPS + AGO100).
📊
Key Findings & Data:Rats from all 4 groups were killed after 12 hours, and theirlungs were quickly collected.
💡
Conclusion & Impact:The histopathology results supported the molecular results.Conclusion: In this experimental study, we demonstrated for the first time the positive effects of AGO onLPS-induced sepsis in lung tissue using molecular and histopathological methods, indicating that it contributesto the prevention of lung damage
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: We designed an experimental model of sepsis in rats to investigate the effects of agomelatine(AGO) on lung tissues using molecular and histopathological methods.Materials and Methods: In our experimental model, the 32 rats were divided into 4 groups: group 1: controlgroup (HEALTHY); group 2: lipopolysaccharide group (LPS); group 3: LPS plus 50 mg/kg AGO group (LPS +AGO50); and group 4: LPS plus 100 mg/kg AGO group (LPS + AGO100). An LPS-induced sepsis model wasperformed to replicate the pathology of sepsis. Rats from all 4 groups were killed after 12 hours, and theirlungs were quickly collected. To investigate the therapeutic strategy, we evaluated tumor necrosis factoralpha (TNF-α) and nuclear factor-kappa B (NF-κB) messenger RNA expressions by real-time polymerasechain reaction using molecular methods and lung tissue damage indicators using histopathological methods.Results: The expressions of TNF-α and NF-κB were reduced in the groups treated with AGO. The histopathology results supported the molecular results.Conclusion: In this experimental study, we demonstrated for the first time the positive effects of AGO onLPS-induced sepsis in lung tissue using molecular and histopathological methods, indicating that it contributesto the prevention of lung damage

🔖

Cite This Article

Köse, D., Halıcı, Z., Çadırcı, E., Yüksel, T. N., Gürbüz, M. A. (2022). The Effects of Agomelatine Treatment on Lipopolysaccharide-Induced Septic Lung Injuries in Rats. Eurasian Journal of Medicine, Cilt: 53 - Sayı: 2, 160–161. https://ajindex.com/articles/508836

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348(16):1546-1554. [Crossref] 2. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(21):2062- 2063. https://doi.org/10.1056/NEJMc1312359 3. Force TR, Saul JD, Lewis M, Thompson T. Acute respiratory distress syndrome. Patient position and motion strategies. Respir Care Clin N Am. 1998;4(4):665-77, viii. 4. Ugan RA, Cadirci E, Halici Z, Toktay E, Cinar I. The role of urotensin-II and its receptors in sepsis-induced lung injury under diabetic conditions. Eur J Pharmacol. 2018;818:457-469. [Crossref] 5. Deitch EA. Animal models of sepsis and shock: a review and lessons learned. Shock. 1998;9(1):1- 11. [Crossref] 6. Esmon CT. Why do animal models (sometimes) fail to mimic human sepsis? Crit Care Med. 2004;32(5 Suppl):S219-222. [Crossref] 7. Parker SJ, Watkins PE. Experimental models of gram-negative sepsis. Br J Surg. 2001;88(1):22- 30. [Crossref] 8. Barroqueiro ES, Prado DS, Barcellos PS, et al. Immunomodulatory and Antimicrobial activity of babassu mesocarp improves the survival in lethal sepsis. Evid Based Complement Alternat Med. 2016;2016:2859652. [Crossref] 9. Habtemariam S, Daglia M, Sureda A, Selamoglu Z, Gulhan MF, Nabavi SM. Melatonin and Respiratory Diseases: A Review. Curr Top Med Chem. 2017;17(4):467-488. [Crossref] 10. Yu GM, Kubota H, Okita M, Maeda T. The anti-inflammatory and antioxidant effects of melatonin on LPS-stimulated bovine mammary epithelial cells. PLoS One. 2017;12(5):e0178525. [Crossref] 11. Ma N, Zhang J, Reiter RJ, Ma X. Melatonin mediates mucosal immune cells, microbial metabolism, and rhythm crosstalk: a therapeutic target to reduce intestinal inflammation. Med Res Rev. 2020;40(2):606-632. [Crossref] 12. Conway S, Canning SJ, Howell HE, et al. Characterisation of human melatonin mt(1) and MT(2) receptors by CRE-luciferase reporter assay. Eur J Pharmacol. 2000;390(1-2):15-24. [Crossref] 13. Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron. 1994;13(5):1177-1185. [Crossref] 14. Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci. 2003;8:d1093-1108. [Crossref] 15. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;27(2):1